Compass Therapeutics’ stock has dropped by more than 60% after a Phase II/III trial of its biliary tract cancer (BTC) ...

Compass Therapeutics (NASDAQ:CMPX) executives highlighted what CEO and Vice Chair Dr. Thomas Schuetz called “absolutely ...

While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.

Investing.com -- Compass Therapeutics (NASDAQ:CMPX) shares tumbled 80% Monday following mixed results from its Phase II/III COMPANION-002 trial evaluating tovecimig combined with paclitaxel in ...

Tovecimig (CTX-009) in combination with paclitaxel significantly improved progression-free survival (PFS), but not overall ...

A compass used by Lewis and Clark on their expedition to explore the American West is owned by the Smithsonian and is part of NPR's 250th anniversary series, America In Pursuit.

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of ...

The U.S. Consulate in Winnipeg brought Bowe to Winnipeg for two days as part of its celebration of the 250th anniversary of ...

Compass Therapeutics Inc. CMPX shares are tumbling on Monday as the company announced results from its COMPANION-002 study, ...

HT Drinks Group, the UK’s largest independent and specialist drinks wholesaler, said the move strengthens its focus on international growth.

A routine cancer scan could soon double as a free heart health check under an innovative new approach being developed ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...